Humacyte ( (HUMA) ) has released its Q3 earnings. Here is a breakdown of the information Humacyte presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Humacyte, Inc. is a biotechnology platform company specializing in the development of universally implantable bioengineered human tissues, aimed at transforming medical practices and improving patient outcomes. The company operates in the biotechnology sector, focusing on advanced tissue constructs and organ systems.
In the third quarter of 2025, Humacyte reported total revenues of $753,000, with significant progress in its product pipeline, including a planned Biologics License Application (BLA) filing for dialysis and advancements in cardiac bypass graft surgery. The company’s Symvess product saw a substantial increase in sales, attributed to increased hospital approvals and inclusion in the U.S. Defense Logistics Agency’s Electronic Catalog.
Key financial highlights include a net loss reduction to $17.5 million from $39.2 million in the same quarter of the previous year, driven by decreased operating expenses and a non-cash remeasurement of contingent earnout liability. Research and development expenses decreased, while selling, general, and administrative expenses saw a slight increase due to the commercial launch of Symvess. The company also reported cash, cash equivalents, and restricted cash totaling $19.8 million as of September 30, 2025.
Strategically, Humacyte is advancing its acellular tissue engineered vessel (ATEV) for dialysis, with positive results from the V007 Phase 3 trial, and is preparing for a first-in-human study of its coronary tissue engineered vessel (CTEV) in 2026. The company also expanded its intellectual property with a new U.S. patent for a bioengineered esophagus.
Looking ahead, Humacyte remains focused on executing its strategic plans, including the commercialization of Symvess and advancing its pipeline products through regulatory processes. The management is optimistic about the potential market acceptance and the anticipated benefits of its bioengineered products in improving patient care.